Abstract Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive tumours. ER positive tumours exhibit low proliferation and ER negative cancers high proliferation. The aim of this study was to determine to what extent the better response of ER negative cancers correlates with proliferation rate. A retrospective analysis of a prospectively maintained database identified 175 neoadjuvant chemotherapy patients with tissue available for Ki67 analysis. On univariate analysis, pre-therapy Ki67 (P = 0.04), ER status (P = 0.002), HER2 status (P = 0.004) and grade (P = 0.0009) were associated with a pCR. In a multivariate model, HER2 was the only significant predictor of pCR. No significant relationship between pre-therapy Ki67 and relapse-free and overall survival was demonstrated. Ki67 is not an independent predictor of clinical CR or pCR. Aspects of ER status beyond its inverse relationship with proliferation may contribute to its predictive value for pCR.
Introduction
The administration of neoadjuvant chemotherapy is well established in the treatment of large potentially operable and locally advanced breast cancer [1] . Large randomised trials have demonstrated no significant difference in survival between patients treated with adjuvant and neoadjuvant chemotherapy [1] . Albeit, not perfect, pathological complete response (pCR), following neoadjuvant chemotherapy, has been shown to be a good surrogate marker for overall survival. In fact women achieving a pCR following neoadjuvant therapy have significantly better survival compared to those with residual carcinoma [1] .
There is evidence to suggest that ER negative tumours are more likely to achieve a pCR following neoadjuvant chemotherapy compared to ER positive cancers [2] [3] [4] . An inverse relationship exists between ER expression and proliferation as assessed by various methods including the MIB-1 antibody against Ki67 [2, 3, 5] , with ER positive cancers showing low proliferation rates, whereas ER negative breast cancers show high proliferation rates. Most investigators have confirmed that high proliferation is associated with a better short-term response to neoadjuvant chemotherapy [5] [6] [7] . However, previous studies of women treated with or without adjuvant chemotherapy have demonstrated that patients with high proliferation have a poor long-term outcome [6] . In fact, despite having a poorer prognosis, patients with triple negative (ER, PgR and HER2 negative) cancers have the highest prevalence of pCR following neoadjuvant chemotherapy [8] .
This study aimed to determine to what extent the better response rate of ER negative tumours to neoadjuvant chemotherapy is potentially explained by their high proliferation. This would be clinically significant because the inverse relationship between ER and proliferation is not absolute: if the determinant of response was proliferation and not ER, proliferation rather than ER should be measured and used for prediction of response to neoadjuvant chemotherapy. The second aim was to determine the influence of pre-chemotherapy proliferation on long-term outcome in a cohort of breast cancer patients treated with neoadjuvant chemotherapy.
Patients and methods

Clinical methodology
A retrospective analysis of a prospectively maintained clinical database was performed to identify patients treated with neoadjuvant chemotherapy for operable or locally advanced breast cancer between 1985 and 2005. In order to address the first aim of the study, patients treated with neoadjuvant chemotherapy alone (i.e. those treated with no endocrine therapy for the neoadjuvant period with ER positive tumours) were selected. Patients with ER negative tumours treated with concurrent neoadjuvant tamoxifen were included in this study, as tamoxifen has minimal activity in such cases. Neoadjuvant chemotherapy regimens included: (1) 2 ). Treatment was usually given to a total of 6 courses, and occasionally to eight in specific trials. Sixty-two of the patients selected were also included in another study assessing the prognostic value of pre-and post-neoadjuvant chemotherapy Ki67 [9] .
The association between pathological and clinical response with the following pre-neoadjuvant chemotherapy factors was assessed; age, menstrual status, clinical T and N stage, initial operability (i.e. operable or locally advanced), Ki67, ER, PgR, HER2, grade, histological type (invasive ductal and lobular), treatment with an anthracycline-based regimen or not and dual ER and HER2 negative phenotype.
The influence of the following factors with relapse-free (RFS) and overall (OS) survival was investigated: Clinical response was assessed according to World Health Organisation criteria, following each cycle of chemotherapy by measuring the two largest diameters of the tumour [10] . Those with no residual invasive or in situ disease were classified as having achieved a pCR [10] .
Surgical and post-operative management followed standard institutional guidelines as described elsewhere [10] . Prior to 1995, women achieving a clinical CR to neoadjuvant chemotherapy were frequently offered the option of radiotherapy without surgery. This approach was discontinued following a retrospective analysis of these patients, which demonstrated a high local recurrence rate [11] .
Tissue acquisition
Tissue was acquired using standard techniques [9] . Haematoxylin and eosin staining was performed to obtain the histological type and where possible the histological grade as part of routine clinical management [12] .
Immunohistochemistry
A standard procedure for Ki67 staining was followed [9] , 4 lm sections were dewaxed in xylene and then hydrated by means of a series of graded ethanol baths and rinsed in water. Endogenous peroxidase activity was blocked. By microwaving at full power (750 W) in citrate buffer pH 6.0 for 10 min antigen retrieval was performed. MIB-1 primary antibody (Dako, Denmark) was used at a dilution of 1:50, and incubated for an hour at room temperature. All washes and dilutions were performed with phosphate-buffered saline (PBS). Biotinyalated rabbit anti-mouse immunoglobulin was applied and subsequently avidinbiotin complex (ABC; Dako). Diaminobenzene (DAB; Sigma, USA) was applied to develop peroxidase activity and counterstaining performed with haematoxylin. The observer (blinded to patient outcome) examined stained sections using a standard light microscope 409 objective using a 10 9 10 eye-piece graticule. Ki67 score was defined as the percentage of total number of tumour cells (at least 1,000) with nuclear staining over 10 high powered fields (409).
The same staining procedure as described above, with microwave antigen retrieval, was used for ER. The primary antibody used 6F11 (Novocastra, UK) was incubated at a dilution of 1:40 for 2 hr at room temperature. The Histoscore (H-score) was used to assess ER, incorporating evaluation of intensity of stain (0-3) and number of cells staining (range of score 0-300). Using this method ER positive tumours have a score of [1.
The Hercep test (Dako) was used to perform HER2 immunohistochemistry. Specimens were classified as positive if immunohistochemical staining was 3? or if staining was 2? and FISH (fluorescence in situ hybridisation) positive. PgR was evaluated using the Allred score [13] .
Statistical analysis
Associations between two variables were assessed as follows: nominal tabulated data were analysed using the Chi-squared test (for 2 9 2 tables Fisher's exact test was used); if one factor was ordinal the Kruskal-Wallis test was used if more than two groups were being compared, the Mann Whitney test for trend being employed to compare two groups. If two ordinal factors were being assessed Spearman Rank correlation was employed. Multivariate analysis of pCR (a binary variable) was undertaken using logistic regression. Univariate and multivariate analysis of RFS and OS was carried out using Cox regression. RFS was defined as the time from the date of presentation to the date of first local relapse, distant relapse or occurrence of a new primary tumour. OS was defined as the time from presentation to death. Patients without an event were censored at the time of last follow-up.
Multivariate analysis was performed in a forward stepwise fashion, the most significant additional variable (satisfying P \ 0.05) being added at each stage, cases with missing values for any of the variables in the model were excluded from analysis. About 95% confidence intervals were used to express ranges within which true parameter values were likely to lie.
All P values were two-tailed and 95% confidence intervals were employed for all tests.
For Ki67 analysis, the centred linear component was first calculated by log transforming the variable and the average of all log transformed values was then deducted from each log transformed observation. This had the effect of 'centering' the values, e.g. the average would be zero and values below the average would be below zero, those above the average would be above zero. A 'centred' quadratic component was then calculated by squaring this linear component and similarly a cubic component was calculated by cubing the linear component. The centred quadratic variable would allow a U-shaped relationship between outcome and the factor to be detected, e.g. low values could be high risk relative to values in the middle of the distribution and similarly high values would also be high risk. Fitting the linear, quadratic and cubic components, or any combination of them allows investigation of the pattern between the log hazard of death (or of relapse, or log odds ratio of response) to be investigated.
Results
The clinical characteristics of 175 patients with pre-therapy histopathology blocks that had sufficient material available for immunohistochemical assessment of Ki67 are displayed in Table 1 . The median age was 48 years, with a range of 26 to 75 years. At the time of analysis 56 patients had died and 71 had relapsed.
A significant association between pre-therapy Ki67 and histological grade (P \ 0.001) was observed and an inverse association with ER status (P = 0.0004). No association between pre-therapy Ki67 and HER2 was seen (P = 0.9). Pathological response
Patients with higher pre-therapy Ki67 were significantly more likely to achieve a pCR than those with lower pretherapy Ki67 (P \ 0.04; Table 2 ). Lack of ER expression, HER2 positivity and high tumour grade were significantly associated with higher pCR rates (P = 0.002, P = 0.004 and P = 0.0009, respectively). No statistically significant correlation between pCR and other clinicopathological variables was observed (age, menopausal status, clinical T and N stage, initial operability, PgR status, dual ER/ HER2 negative phenotype, histological type and treatment with an anthracycline-based regimen).
Multivariate analysis was performed with and without HER2 included in the model (Table 2) . Pre-therapy grade and ER status were found to be independent predictors of pCR, but not Ki67. When included in the model HER2 status was a significant independent predictor of pCR (P = 0.04), but ER status and grade lost significant independent predictive value.
Clinical response
On univariate and multivariate analyses, high histological grade was associated with more prevalent clinical response (P = 0.01). No significant correlation between clinical response and the other clinicopathological variables was observed (Table 2) .
Relapse-free survival
On univariate analysis the following factors were significantly associated with shorter RFS; higher clinical T (P \ 0.001) and higher N (P \ 0.001) stage, locally advanced disease status (P = 0.05), higher pre-therapy Ki67 (P \ 0.001), pre-therapy ER negativity (P = 0.004), dual ER/ HER2 negative (P = 0.002), clinical progressive disease (P = 0.003), type of surgery performed (P = 0.01) and no adjuvant endocrine therapy (P \ 0.001; Table 3 ). A trend for improved RFS was observed in patients with lower pre-therapy grade (P = 0.06) and those achieving a pCR (P = 0.07).
On multivariate analysis, higher clinical T (P \ 0.001) and higher N (P = 0.001) stage, locally advanced disease status (P = 0.02), ER negativity (P = 0.04), lack of clinical response to chemotherapy (P = 0.001) and no adjuvant endocrine therapy (P = 0.001) were significant independent factors for shorter RFS.
Overall survival
On univariate analysis the following factors were associated with shorter OS; higher clinical T (P = 0.001) and N stage (P = 0.01), pre-therapy Ki67 (linear function, P = 0.03 and quadratic function, P = 0.01), treatment with non-anthracycline-based neoadjuvant regimens (P = 0.03), lack of cCR to first-line chemotherapy (P = 0.02), the absence of a pCR to neoadjuvant therapy (P = 0.05), mastectomy as opposed to breast conserving surgery (P \ 0.001) and no adjuvant endocrine therapy (P = 0.001; Table 4) .
On multivariate analysis, higher clinical T (P \ 0.001) and higher N (P = 0.001) stage, locally advanced disease status (P = 0.03), type of surgery performed (P = 0.03) and no adjuvant endocrine therapy (P = 0.005) were the only independent prognostic factors associated with shorter OS.
Discussion
Pathological complete response to neoadjuvant chemotherapy is a clear predictor of survival. We have previously shown that in patients who do not achieve a pCR, postneoadjuvant chemotherapy Ki67 to be an independent prognostic factor [9] . The aim of the current study was to assess the prognostic and predictive role of pre-therapy Ki67. Pre-therapy Ki67, grade, ER and HER2 status were significant predictors of pCR on univariate analysis. However, in a multivariate model, HER2 status was the only significant independent predictor of pCR. These findings corroborate those of previous studies, where grade [2, 14] and HER2 [15, 16] were shown to be significant independent predictors of pCR in multivariate models including Ki67, HER2 and ER status. Furthermore, in analysing ER positive and negative subgroups separately, Ki67 did not have a significant influence on pCR (data not shown). Here we demonstrate that the inverse correlation between ER status and Ki67 does not fully explain the higher pCR rate observed in ER negative tumours. This effect is unlikely to be due to ER status per se, but may in part be explained by HER2 status. These observations regarding the sensitivity of HER2 positive tumours to anthracycline chemotherapy may due to frequent co-amplification of HER2 and topoisomerase II [17] . In contrast, other investigators have found Ki67 to be an independent predictor of pCR in models including histological grade, ER and HER2 status [17] [18] [19] [20] . These discordant results may be due to the small patient numbers, the heterogeneous patient populations and chemotherapy regimens analysed and the investigation of varying biomarkers in each individual study as well as differing selection criteria. Another major limitation of most of these studies (including the present) is their retrospective nature.
Predictors of a pCR to neoadjuvant chemotherapy are also markers of poorer survival. However, recent studies have shown that women with triple negative tumours have a higher pCR rate than those with non-triple negative tumours [8, 21, 22] . Furthermore, those with triple negative disease who do achieve a pCR to neoadjuvant chemotherapy have an excellent prognosis. However, triple negative patients with residual disease following neoadjuvant therapy have worse survival compared to those with non-triple negative tumours [8, 21, 22] .
There has been inconsistency regarding the prognostic value of clinical response to neoadjuvant chemotherapy possibly due to inter observer variability, and therefore for the purpose of this study clinical response is not as good an end point as pCR. Our study did not show a significant independent correlation between pre-therapy Ki67 and clinical response.
ER status, clinical T and N stage and the use of adjuvant endocrine therapy were independent prognostic factors for RFS in our study. On multivariate analysis pre-therapy Ki67 was not an independent predictor of RFS or OS. In agreement, most other studies have demonstrated that preneoadjuvant chemotherapy Ki67 is not an independent predictor of relapse-free, disease-free and progression-free survival [2, 15, 16, 18, [23] [24] [25] [26] [27] , or OS [16, 19, [23] [24] [25] [26] [27] . A recent meta analysis, of patients treated with and without adjuvant systemic chemotherapy, has found that high Ki67 is associated with worse survival [28] . Further studies assessing the predictive impact of Ki67 in specific chemotherapy regimens are warranted.
In conclusion, pre-therapy ER and Ki67 were predictors of pCR on univariate analysis. However, in a multivariate model (including grade, ER and HER2 status), Ki67 lost significance. This suggests that aspects of ER status beyond its inverse association with proliferation may contribute to its predictive value for pCR. This in part may be explained by the inverse correlation observed between ER and HER2 status. Pre-therapy Ki67 was not an independent predictor of RFS and OS. 
